台灣臨床試驗主持人資料庫|TPIDB

2016-06-01 - 2019-08-31

Phase II

An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE031C2201

Condition/Disease

Chronic Spontaneous Urticaria
Test Drug

QGE031

Participate Sites
3Sites

Terminated3Sites

鐘文宏

Linkou Chang Gung Medical Foundation

Division of Dermatology

2018-09-01 - 2022-08-03

Phase III

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Condition/Disease

Chronic Spontaneous Urticaria (CSU)
Test Drug

QGE031/ligelizumab

Participate Sites
3Sites

Recruiting3Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Condition/Disease

Obesity
Test Drug

Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

Condition/Disease

Hepatocellular Carcinoma (HCC)
Test Drug

ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Condition/Disease

Non-small cell lung cancer
Test Drug

HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-06-01 - 2018-12-31

Phase I

A prospective, open-label, dose escalation phase 1 first-in-human study to investigate the safety, and tolerability and to determine the maximum tolerated dose and recommended phase 2 dose of a recombinant anti-EGFR humanized monoclonal antibody, HLX07, in patients with advanced solid cancers

Condition/Disease

solid tumor
Test Drug

HLX07

Participate Sites
3Sites

Terminated3Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-04-30 - 2022-10-31

Phase II/III

A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

Condition/Disease

FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy
Test Drug

BAY 1163877

Participate Sites
7Sites

Terminated6Sites

馮思中

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

Condition/Disease

Axial Spondyloarthritis
Test Drug

KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬

Linkou Chang Gung Medical Foundation

黃春明

China Medical University Hospital-Taipei

未分科

2016-02-01 - 2020-06-30

Phase III

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

張文震

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-11-01 - 2020-02-17

Phase III

A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive

Condition/Disease

Rheumatoid Arthritis
Test Drug

Abatacept

Participate Sites
4Sites

Terminated4Sites

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

Search Result

List